under this Drug Safety Enhancement Act which Mr. Dingell and some of us introduced yesterday, would that give the FDA new authorities to address issues like intentional economic adulteration like in the heparin situation?
DeGette questions the effectiveness of the Drug Safety Enhancement Act regarding FDA authorities.
Share & report
More from Diana DeGette
I think it is important that we continue to keep eyes on that issue to make sure that it is still continuing to happen.
How you implement and administer consistent policies, I think, has been a challenge.
It is a little embarrassing for someone like me, who is trying to tell colleagues around the world that we need to have robust oversight, that the U.S. Congress is actually having an oversight hearing that is so vague that you can't…
People like me who represent underserved communities know that these communities frequently have--they're low-income, disadvantaged, minority communities.
Other voices in this conversation
